

# Graeme C Young

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8049294/graeme-c-young-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23  
papers

421  
citations

13  
h-index

20  
g-index

28  
ext. papers

509  
ext. citations

5.6  
avg, IF

2.99  
L-index

#	Paper	IF	Citations
23	Metabolism and disposition of vilanterol, a long-acting (2)-adrenoceptor agonist for inhalation use in humans. <i>Drug Metabolism and Disposition</i> , <b>2013</b> , 41, 89-100	4	39
22	Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 1185-200	3.8	32
21	Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors. <i>Journal of Clinical Pharmacology</i> , <b>2013</b> , 53, 955-61	2.9	31
20	Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study. <i>BMC Pharmacology &amp; Toxicology</i> , <b>2013</b> , 14, 14	2.6	30
19	Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 524-32	3.8	29
18	European Bioanalysis Forum recommendation: scientific validation of quantification by accelerator mass spectrometry. <i>Bioanalysis</i> , <b>2012</b> , 4, 2669-79	2.1	23
17	New frontiers-accelerator mass spectrometry (AMS): Recommendation for best practices and harmonization from Global Bioanalysis Consortium Harmonization Team. <i>AAPS Journal</i> , <b>2014</b> , 16, 357-9	3.7	17
16	Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibiotic. <i>Drug Metabolism and Disposition</i> , <b>2013</b> , 41, 1070-81	4	17
15	Phase 0/microdosing approaches: time for mainstream application in drug development?. <i>Nature Reviews Drug Discovery</i> , <b>2020</b> , 19, 801-818	64.1	17
14	AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration. <i>Bioanalysis</i> , <b>2011</b> , 3, 393-405	2.1	15
13	Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humans. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 415-30	4	13
12	Phase 0, including microdosing approaches: Applying the Three Rs and increasing the efficiency of human drug development. <i>ATLA Alternatives To Laboratory Animals</i> , <b>2018</b> , 46, 335-346	2.1	13
11	Determination of salmeterol in rat and dog plasma by high-performance liquid chromatography with fluorescence detection. <i>Journal of Pharmaceutical Sciences</i> , <b>1993</b> , 82, 323-5	3.9	12
10	Best practices for metabolite quantification in drug development: updated recommendation from the European Bioanalysis Forum. <i>Bioanalysis</i> , <b>2016</b> , 8, 1297-305	2.1	12
9	Application of (14)C-accelerator MS in pharmaceutical development. <i>Bioanalysis</i> , <b>2015</b> , 7, 513-7	2.1	10
8	An AMS method to determine analyte recovery from pharmacokinetic studies with concomitant extravascular and intravenous administration. <i>Bioanalysis</i> , <b>2011</b> , 3, 407-10	2.1	10
7	A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 482-489	3.8	7

6	An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. <i>Drug Metabolism and Disposition</i> , <b>2019</b> , 47, 1457-1468	4	6
5	Open-Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently. <i>Clinical Pharmacology in Drug Development</i> , <b>2019</b> , 8, 188-197	2.3	5
4	Pharmacokinetics, Excretion, and Mass Balance of [ <sup>14</sup> C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men. <i>Clinical Pharmacology in Drug Development</i> , <b>2018</b> , 7, 901-910	2.3	4
3	THE VALUE OF METABOLITE IDENTIFICATION AND QUANTIFICATION IN CLINICAL STUDIES. SOME CASE STUDIES ENABLING EARLY ASSESSMENT OF SAFETY IN HUMANS 275-291		3
2	AMS in drug development: Exploring the current utility of AMS and future opportunities for absolute bioavailability and ADME investigations <b>2020</b> , 185-210		1
1	Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination. <i>Clinical Pharmacology in Drug Development</i> , <b>2021</b> , 10, 1419-1431	2.3	0